

Best of ASCO 2012 in Japan フログラム

as of 21 June /2012

※本セミナーでとりあげる演題は、2012年6月上旬に開催された米国臨床腫瘍学会 (ASCO) の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のプログラム委員会が選定したものです。但し、IDI* 印のある演題は日本臨床腫瘍学会のプログラム委員会が独自で選定したものです。

7月7日(土曜日)

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00- 10:10	Welcome & Introduction 秋田 弘俊 北海道大学				
10:10- 10:45	消化器がん Colorectal Cancer 設案 紘平 国立がん研究センター 東病院	朴 成和 聖マリアンナ医科大学	CRA 3503	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).	Dirk Arnold, MD
			3502	Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC).	Eric Van Cutsem, MD, PhD
			3508	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.	Bernard Nordlinger, MD
			3505	Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.	Carmen Joseph Allegra, MD
10:45-10:55	Discussion: Q&A				
10:55-11:30	Melanoma 山崎 直也 国立がん研究センター 中央病院	南 博信 神戸大学医学部附属病院	LBA 8500	BREAK 3: A randomized, phase III, open-label, multicenter trial comparing the selective BRAF kinase-inhibitor dabrafenib (GSK2118436) with dacarbazine in treatment-naïve, unresectable or metastatic melanoma patients with BRAF ^{V600E} mutation.	Axel Hauschild, M.D.
			LBA 8509	METRIC: A phase III randomized, open-label study comparing trametinib (GSK1120212) to chemotherapy (CT) in CT-naïve or pre-treated patients with advanced or metastatic BRAF ^{V600E/K} mutation-positive melanoma.	Caroline Robert, MD, PhD
			8504	Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.	Lawrence E. Flaherty, MD
			8507	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).	F. Stephen Hodi, MD
11:30-11:40	Discussion: Q&A				
11:40-12:00	Sarcoma 内藤 陽一 国立がん研究センター 東病院	秋田 弘俊 北海道大学	LBA 10008	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.	George D. Demetri, MD
12:00-12:10	Discussion: Q&A				
12:10-12:25	Break 15分				
12:25-13:25	[ランチョンセミナー] 久保田 馨 日本医科大学付属病院	西條 長宏 近畿大学	「Ⅳ期非小細胞肺癌の化学療法」 国内臨床第Ⅲ相試験を診療にどう活かすか: CATS TRIAL結果より 共催: 大鵬薬品工業株式会社		
13:25-13:40	Break 15分				
13:40-14:10	消化器がん Noncolorectal 加藤 健 国立がん研究センター 中央病院	馬場 英司 九州大学病院	LBA 4003	Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.	Thierry Conroy, MD
			LBA 4000	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab in previously untreated advanced esophagogastric cancer (REAL3).	Tom Samuel Waddell, MBChB, MRCP
			4002*	Randomized phase III study of irinotecan (CPT-11) vs. weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.	Shinya Ueda
14:10-14:20	Discussion: Q&A				
14:20-14:55	Developmental Therapeutic 清水 俊雄 近畿大学	瀬戸 貴司 国立病院機構 九州がんセンター	3000*	Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.	Jean-Charles Soria
			3002*	Phase I study of OPB51602, a small molecule inhibitor of STAT3 phosphorylation, in patients with refractory solid malignancies.	Boon C. Goh
			3003*	A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.	Philippe Bedard
			3008*	A first-in-human phase I study of the oral Notch inhibitor LY900009 in patients with advanced cancer.	Shubham Pant
14:55-15:05	Discussion: Q&A				
15:05-15:20	Coffee Break 15分				
15:20-16:00	泌尿器がん 内野 慶太 九州医療センター	中川 昌之 鹿児島大学病院	4	Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.	Maha Hussain, MD, FACP
			4501	Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.	Robert John Motzer, MD
			4519	Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.	Johann Sebastian De Bono, MB, ChB, FRCP, MSc, PhD
			LBA 4518	Interim analysis results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).	Charles J. Ryan, MD
			LBA 4512	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).	Chris Parker, MD, MRCP
16:00-16:10	Discussion: Q&A				
16:10-16:45	婦人科がん 松本 光史 兵庫県立がんセンター	勝俣 範之 日本医科大学武蔵小杉病院	5006	A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505).	Ryo Kitagawa, MD
			5003	Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer: JGOG 3016 trial.	Noriyuki Katsumata, MD, PhD
			LBA 5002	AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) combined with chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).	Eric Pujade-Lauraine, M.D., Ph.D.
			LBA 5000	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCG and EORTC-GCG study.	Ignace B. Vergote, MD, PhD
16:45-16:55	Discussion: Q&A				

7月8日(日曜日)

Time	講師	司会	ASCO演題		
7:30	開場		ID	Abstract Title	Author
8:00-8:45	[モーニングセミナー] 岡本 勇 近畿大学	南 博信 神戸大学医学部附属病院	演題:「Best of Molecular-Targeted Therapy – ASCO 2012 –」 共催:ファイザー株式会社		
8:45-9:00	Break				
9:00-9:35	乳がん Triple Negative/ Cytotoxics/ Local Therapy 向井 博文 国立がん研究センター 東病院	田村 研治 国立がん研究センター 中央病院	CRA 1002	CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).	Hope S. Rugo, MD
			LBA 1000	NSABP B-38: Definitive analysis of patient outcome from a randomized trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.	Sandra M. Swain, MD
			1003	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).	Yeon Hee Park
			1004	RTOG 9804: A prospective randomized trial for "good risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS)	Beryl McCormick, MD
9:35-9:45	Discussion: Q&A				
9:45-10:20	乳がん HER2/ER 佐治 重衡 京都大学	清水 千佳子 国立がん研究センター 中央病院	LBA1	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.	Kimberly L. Blackwell, MD
			502	Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): Treatment effects are influenced by menopausal status rather than age.	Helen Marshall, MSc
			501	Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.	Lois E. Shepherd, MD
			LBA 671*	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.	Karen A. Gelmon
10:20-10:30	Discussion: Q&A				
10:30-11:05	Patient and Survivor Care 高野 利実 虎の門病院	関根 郁夫 千葉大学	CRA 9013	CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).	Ellen M. Lavoie Smith, PhD, APRN, AOCN(R)
			9000	Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial.	Qamar J. Khan, MD
			9001	Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2.	Debra L. Barton, PhD, AOCN, FAAN, RN
			4008	A randomized controlled phase II study of the theprophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma.	Zhenggang Ren
11:05-11:15	Discussion: Q&A				
11:15-11:45	頭頸部がん 岡野 晋 東京慈恵会医科大学 附属病院	安藤 雄一 名古屋大学医学部附属病院	5508	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.	Patrick Schoffski, MD, MPH
			5500	DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).	Ezra E.W. Cohen, MD
			5501	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).	Robert I. Haddad, MD
11:45-11:55	Discussion: Q&A				
11:55-12:10	Break				
12:10-13:10	[ランチョンセミナー] 勝俣 範之 日本医科大学武蔵小杉病院	田村 和夫 福岡大学病院	テーマ:「発熱性好中球減少症のマネジメント」 共催:協和発酵キリン株式会社		
13:10-13:25	Break				
13:25-14:00	血液 Leukemia , Myelodysplasia and Transplantation 山本 一仁 愛知県がんセンター 中央病院	照井 康仁 がん研有明病院	6503	PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.	Jorge E. Cortes, MD
			6507	The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.	John C. Byrd, MD
			6504	Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.	Andreas Hochhaus, MD
			6501	Inotuzumab ozogamycin (IO), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL).	Elias Jabbour, MD
14:00-14:10	Discussion: Q&A				
14:10-14:50	血液 Lymphoma & Plasma Cell Disorders 小林 幸夫 国立がん研究センター 中央病院	薄井 紀子 東京慈恵会医科大学附属 第三病院	8006	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).	Massimo Federico, MD
			8002	ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.	Patrice P. Carde, MD, PhD
			3	Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StIL NHL1 study.	Mathias J. Rummel, MD, PhD
			8011	Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).	Andrzej J Jakubowiak, MD, PhD
			9500	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.	Yael P. Mosse, MD
14:50-15:00	Discussion: Q&A				
15:00-15:35	肺がん 藤原 豊 国立がん研究センター 中央病院	岡本 勇 近畿大学	7509	Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).	Julie R. Brahmer, MD
			LBA 7500	LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.	James Chih-Hsin Yang, MD, PhD
			LBA 7501	TAILOR: Phase III trial comparison of erlotinib versus docetaxel in the second-line treatment of wild type (wt) EGFR patients with NSCLC.	Marina Chiara Garassino, MD
			LBA 7507*	PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous(NS) non-small cell lung cancer(NSCLC).	Luis Paz-Ares
15:35-15:45	Discussion: Q&A				
15:45-16:00	Closing Remarks 南 博信 神戸大学医学部附属病院				